Number] Shares Xencor, Inc. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT [Date], 2013Underwriting Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • New York
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 27, 2010 (the “Effective Date”) by and between XENCOR, INC., a Delaware corporation with its principal offices at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”), and MORPHOSYS AG, a German corporation with its principal offices at Lena-Christ-Strasse 48, 82152 Martinsried/Planegg, Germany (“MorphoSys”).
DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENTDevelopment and Manufacturing Services Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • Ohio
This Development and Manufacturing Services Agreement (“Agreement”) is made as of this 15th day of September, 2005 (“Effective Date”), by and between Xencor, Inc., a Delaware corporation, with a place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (hereinafter “Xencor”) and Cardinal Health PTS, LLC, a Delaware limited liability company, by and through its Gala Biotech business unit with a place of business at 8137 Forsythia Street, Middleton, Wisconsin 53562 (hereinafter “Cardinal Health”).
GPEx®-DERIVED CELL LINE SALE AGREEMENT by and between Catalent Pharma Solutions LLC and Xencor, Inc.Sale Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • Delaware
THIS GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made and is effective this day of December, 2011, (“Effective Date”) by and between Catalent Pharma Solutions LLC, a Delaware Limited Liability company, having a place of business at 8137 Forsythia Street, Middleton, Wisconsin 53562 USA (“Catalent”), and Xencor, Inc., a Delaware corporation, having a place of business at 111 West Lemon Avenue, Monrovia, California 91016 USA (“Xencor”).
CLINICAL SUPPLY AGREEMENTClinical Supply Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • Delaware
THIS CLINICAL SUPPLY AGREEMENT (this “Agreement”) is entered into and effective this 1st day of October, 2012 (“Effective Date”), by and between Cook Pharmica LLC (“COOK”), an Indiana limited liability company with offices at 1300 South Patterson Drive, Bloomington, Indiana 47403 and Xencor, Inc. (“CLIENT”), a Delaware corporation, with offices at 111 West Lemon Avenue, Second Floor, Monrovia, CA, 91016. In this Agreement, COOK and CLIENT each may be referred to individually as a “Party” and together as “Parties.”
OPTION AND LICENSE AGREEMENTOption and License Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations
This OPTION AND LICENSE AGREEMENT (this “Agreement”), effective as of January 28, 2013 (the “Effective Date”), is made by and between Alexion Pharmaceuticals, Inc., a Delaware corporation (“Alexion”), having a principal place of business at 352 Knotter Drive, Cheshire, Connecticut 06410, and Xencor, Inc., a Delaware corporation (“Xencor”), having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016. Alexion and Xencor may each be referred to herein, individually, as a “Party” or, collectively, as the “Parties.”
COLLABORATION AGREEMENTCollaboration Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • New York
COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • California
THIS COLLABORATION AND OPTION AGREEMENT (“Agreement”) dated as of December 22, 2010 (“Effective Date”), is entered into between XENCOR, INC., a Delaware corporation having its principal place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”) and AMGEN INC., a Delaware corporation, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”). Amgen and Xencor are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein shall have the definitions set forth in Article 1.
